ABCC3 was remarkably upregulated in the TMZ-resistant glioma cells (Figures 10H–J) and promoted glioma proliferation (Figure 11), indicating it might be associated with the poor outcome of GBM receiving standard-of-care for concurrent radiotherapy and TMZ-chemotherapy after surgical resection (2, 42). The gene discussed is ABCC3; the disease is glioblastoma.